Upstream Bio (UPB) Preferred Dividend Payments (2023 - 2024)
Upstream Bio (UPB) posted quarterly Preferred Dividend Payments of $548000.0 for Q4 2024, down 82.61% year-over-year from $3.2 million in Q1 2024, and down 89.13% quarter-over-quarter from $5.0 million in Q3 2024.
Upstream Bio (UPB) Preferred Dividend Payments (2023 - 2024) Analysis & Trends
Upstream Bio's Preferred Dividend Payments history runs 2 years deep, the most recent figure standing at $548000.0 for Q4 2024.
- In Q4 2024, Preferred Dividend Payments fell 82.61% year-over-year to $548000.0; the TTM figure through Dec 2025 stood at $548000.0 (down 95.97% YoY), while the FY2024 annual figure was $13.6 million, down 23.3% from the prior year.
- Preferred Dividend Payments for Q4 2024 stood at $548000.0, down from $5.0 million in the prior quarter.
- The five-year high for Preferred Dividend Payments was $5.0 million in Q3 2024, with the low at $548000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Upstream Bio | 387.23 Mn | 387.23 Mn | -3.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 548,000.00 |
| Sep 30, 2024 | 5.04 Mn |
| Jun 30, 2024 | 4.88 Mn |
| Mar 31, 2024 | 3.12 Mn |
| Dec 31, 2023 | 3.15 Mn |
| Sep 30, 2023 | 3.15 Mn |